572.61

0.54% -3.81

Regeneron Pharmaceuticals Inc (REGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché REGN Giù? Forum Previsione

Precedente Chiudi:

$576.42

Aprire:

$583.01

Volume 24 ore:

317.39K

Relative Volume:

0.31

Capitalizzazione di mercato:

$59.58B

Reddito:

$14.21B

Utile/perdita netta:

$4.46B

Rapporto P/E:

14.43

EPS:

39.6877

Flusso di cassa netto:

$3.56B

1 W Prestazione:

+0.60%

1M Prestazione:

-0.30%

6M Prestazione:

+4.37%

1 anno Prestazione:

-43.12%

Intervallo 1D:

$571.95

$589.08

Intervallo di 1 settimana:

$541.00

$589.08

Portata 52W:

$476.49

$1,013.09

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Nome

Regeneron Pharmaceuticals Inc

Settore

Healthcare (1143)

Industria

Biotechnology (636)

Telefono

(914) 847-7000

Indirizzo

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Dipendente

15,207

Cinguettio

@regeneron

Prossima data di guadagno

2025-08-01

Ultimi documenti SEC

REGN's Discussions on Twitter

Confronta REGN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
REGN Regeneron Pharmaceuticals Inc	571.95	60.69B	14.21B	4.46B	3.56B	39.69
VRTX Vertex Pharmaceuticals Inc	409.63	105.69B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	485.31	61.52B	2.46B	-319.09M	-52.09M	-2.4669
ARGX Argen X Se Adr	831.04	50.05B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	318.36	35.25B	4.56B	-176.77M	225.30M	-1.7177

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-14	Iniziato	Rothschild & Co Redburn	Buy
2025-06-30	Downgrade	Argus	Buy → Hold
2025-05-30	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-05-14	Aggiornamento	Citigroup	Neutral → Buy
2025-04-22	Ripresa	Cantor Fitzgerald	Overweight
2025-02-05	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-01-16	Downgrade	UBS	Buy → Neutral
2024-12-10	Ripresa	BofA Securities	Underperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Neutral
2024-09-24	Downgrade	Leerink Partners	Outperform → Market Perform
2024-03-12	Iniziato	Bernstein	Outperform
2024-01-12	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-11-03	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-08-21	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-21	Reiterato	Oppenheimer	Perform
2023-06-28	Downgrade	Canaccord Genuity	Buy → Hold
2023-03-27	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-03-24	Aggiornamento	Jefferies	Hold → Buy
2023-03-23	Aggiornamento	Raymond James	Underperform → Mkt Perform
2023-01-30	Aggiornamento	Cowen	Market Perform → Outperform
2023-01-20	Aggiornamento	JP Morgan	Neutral → Overweight
2022-10-26	Downgrade	Raymond James	Mkt Perform → Underperform
2022-10-17	Downgrade	Evercore ISI	Outperform → In-line
2022-09-09	Aggiornamento	Jefferies	Underperform → Hold
2022-09-09	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-06-06	Iniziato	Jefferies	Underperform
2022-05-23	Iniziato	SVB Leerink	Outperform
2022-01-05	Downgrade	BofA Securities	Neutral → Underperform
2022-01-03	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-12-15	Downgrade	Bernstein	Outperform → Mkt Perform
2021-12-09	Ripresa	Wells Fargo	Overweight
2021-12-07	Ripresa	Cowen	Market Perform
2021-12-06	Iniziato	Goldman	Buy
2021-11-19	Ripresa	BMO Capital Markets	Outperform
2021-11-05	Downgrade	The Benchmark Company	Buy → Hold
2021-06-29	Iniziato	H.C. Wainwright	Buy
2021-01-25	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Aggiornamento	The Benchmark Company	Hold → Buy
2021-01-08	Aggiornamento	Citigroup	Neutral → Buy
2020-10-05	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Downgrade	The Benchmark Company	Buy → Hold
2020-07-09	Aggiornamento	SunTrust	Hold → Buy
2020-05-26	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-04-28	Downgrade	Citigroup	Buy → Neutral
2020-04-17	Aggiornamento	The Benchmark Company	Hold → Buy
2020-04-08	Iniziato	The Benchmark Company	Hold
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-02-26	Aggiornamento	Canaccord Genuity	Hold → Buy
2020-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2020-02-25	Aggiornamento	Jefferies	Hold → Buy
2020-02-11	Aggiornamento	Argus	Hold → Buy
2019-12-24	Iniziato	Raymond James	Mkt Perform
2019-12-16	Downgrade	Evercore ISI	Outperform → In-line
2019-12-13	Aggiornamento	Credit Suisse	Neutral → Outperform
2019-11-12	Iniziato	SunTrust	Hold
2019-11-07	Aggiornamento	Citigroup	Neutral → Buy
2019-10-17	Ripresa	BofA/Merrill	Neutral
2019-09-23	Aggiornamento	Guggenheim	Neutral → Buy

Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

Oct 15, 2025

Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com

Oct 15, 2025

Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Morningstar

Oct 15, 2025

Regeneron to present new data on Libtayo dosing regimen at ESMO By Investing.com - Investing.com South Africa

Oct 15, 2025

Regeneron to present new data on Libtayo dosing regimen at ESMO - Investing.com India

Oct 15, 2025

Regeneron Pharmaceuticals Announces New Oncology Data Presentations at ESMO 2025 Meeting - Quiver Quantitative

Oct 15, 2025

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers - The Manila Times

Oct 15, 2025

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers - GlobeNewswire Inc.

Oct 15, 2025